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Abstract
Objectives: We evaluated patterns of meal intake, insulin bolus delivery, and fingerstick glucose measurements
during hybrid closed-loop and sensor-augmented pump (SAP) therapy, including associations with glucose control.
Methods: Data were retrospectively analyzed from pump-treated adults with type 1 diabetes who underwent, in
random order, 12 weeks free-living closed-loop (n = 32) and 12 weeks SAP (n= 33) periods. We quantified daily
patterns of main meals, snacks, prandial insulin boluses, correction boluses, and fingerstick glucose measure-
ments by analyzing data recorded on the study glucometer and on study insulin pump.
Results: We analyzed 1942 closed-loop days and 2530 SAP days. The total number of insulin boluses was
reduced during closed-loop versus SAP periods by mean 1.0 per day (95% confidence interval 0.6–1.4,
P < 0.001) mainly because of a reduced number of correction boluses by mean 0.7 per day (0.4–1.0,
P < 0.001). Other behavioral patterns were unchanged. The carbohydrate content of snacks but not the
number of snacks was positively correlated with (1) glycemic variability as measured by standard deviation
of sensor glucose (closed-loop P < 0.05; SAP P < 0.01), (2) mean sensor glucose (P < 0.05), and (3) post-
intervention HbA1c (P < 0.05). Behavioral patterns explained 47% of between-subject variance in glucose
variability during SAP period and 30%–33% of variance of means sensor glucose and postintervention
HbA1c.
Conclusion: Fewer correction boluses are delivered during closed-loop period. The size of snacks appears to
worsen glucose control possibly because of carbohydrate-rich content of snacks. Modifiable behavioral patterns
may be important determinants of glucose control.
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Introduction
Over the past decades, advances in continuous glucosemonitoring1 and insulin pump technologies2 have led to
improved care and quality of life in people with type 1 diabetes.
Although the accuracy and reliability of the devices have grad-
ually increased,1 many users do not achieve glucose targets.3
Further improvements in outcomes may be achieved by
linking sensor glucose measurements to insulin delivery such
as when applying low glucose suspend4 or predictive glucose
management approaches5 and ultimately closed-loop glucose
control (the ‘‘artificial pancreas’’), the latter characterized by
automated graduated insulin delivery by insulin pump below
and above preprogramed level directed by a control algorithm.
Twomain configurations of the closed-loop control system, the
single-hormone (insulin-only) and the dual-hormone systems
(i.e., addition of glucagon), have been shown to offer tighter
glucose control than current treatment modalities.6 Given the
delayed absorption of current subcutaneously delivered rapid-
acting insulin analogues, ‘‘hybrid closed-loop systems’’ benefit-
ing from user-initiated prandial insulin boluses appear more
appropriate than the fully closed-loop approach.7 Within the
hybrid closed-loop approach, user interactions may affect out-
comes directly such as when omitting prandial boluses or indi-
rectly through changes in eating habits.
Randomized outpatient clinical trials of the hybrid closed-
loop control system over up to a 3-month period have been
performed6 such as that by Thabit et al. assessing the feasi-
bility, safety, and efficacy of the 12-week home use of a single-
hormone closed-loop control system in comparison with
sensor-augmented pump therapy.8 The medium-term clinical
trials provide an opportunity to enhance our understanding of
behavioral patterns, their changes during the use of the closed-
loop control, and associations with glycemic control. In this
article, we performed a retrospective analysis of the data ob-
tained by Thabit et al.8 to explore these trends.
Research Design and Methods
Study design and participants
We retrospectively analyzed data from an open-label, mul-
ticenter, randomized, crossover trial conducted under free-
living home conditions in adults with type 1 diabetes in the
United Kingdom, Germany, and Austria.8 Each participant
used the hybrid closed-loop system and sensor-augmented
pump therapy (open loop) for a 12-week period. Overall, 33
participants [18 males, 15 females; age (mean– standard
deviation (SD)), 40.0– 9.4 years; duration of insulin pump
therapy, 7.8– 5.9 years; HbA1c at screening, 8.5%– 0.7%;
total daily insulin dose, 0.62– 0.15U/(kg$d)] completed the
12-week period of sensor-augmented pump therapy, while 32
of those successfully completed the 12-week closed-loop pe-
riod. During hybrid closed-loop and sensor-augmented pump
periods, the participants applied bolus wizard to administer
prandial boluses and were able to deliver correction boluses
between meals on their own volition. Detailed information
regarding the study design and results has been published.8
Capture of meal, insulin delivery, and fingerstick
glucose measurement data
During both periods, the participants used study insulin
pump (Dana R Diabecare, Sooil, Seoul, South Korea) that
stored insulin delivery data, including insulin boluses and
meal data entered during the use of bolus wizard. The study
glucometer (FreeStyle Navigator II; Abbott Diabetes Care,
Alameda, CA) stored information about fingerstick glucose
measurements and meals/snacks not accompanied by insulin
bolus. Food diaries were not used.
Data and statistical analysis
Daily (midnight to midnight) behavioral patterns evaluating
eating, insulin bolusing, and glucose self-monitoring habits
were determined from data downloaded from the study gluc-
ometer and study insulin pump, including the number and size
(in grams of carbohydrates) of main meals per day (main meal
defined as that containing 25 g carbohydrates ormore per 70 kg
body weight), the number and size of snacks per day (snack
defined as that containing <25g carbohydrates per 70 kg body
weight), the number of insulin boluses per day, the number of
small boluses per day (defined as <10% of average total daily
dose), the number of correction boluses per day (defined as
<10% of average total daily dose, delivered 15min or more
apart from a meal and at a glucose value at or >8mmol/L), and
the number of fingerstick glucose measurements per day.
Mean sensor glucose, glucose variability as measured by the
standard deviation of sensor glucose, and HbA1c at the end of
study interventions assessed glucose control.
From the closed-loop intervention, we included in the
analysis days during which closed loop was operational for at
least 80% of the time to ensure that glucose control was
mostly directed by the closed-loop system. During both study
periods, days without meals were excluded from the analysis.
Behavioral patterns during closed-loop and sensor-augmented
pump periods were compared using paired t test. Associa-
tions between behavioral patterns and glucose control were
evaluated using the Pearson correlation coefficient. The lin-
ear regression analysis was used to quantify the amount
of explained between-subject variance in glucose control
endpoints as a function of behavioral patterns. The analyses
should be considered hypotheses generating and no correc-
tions for multiple comparisons have been made.
Data processing was performed using Matlab version
2013b (The MathWorks, Inc., Natick, MA) and the statistical
analysis was performed using SPSS version 23 (IBM Soft-
ware, Hampshire, UK). Data are reported as mean – SD un-
less stated otherwise. A value of P < 0.05 was considered
statistically significant.
Results
The total number of days included in the analysis was 4472
(1942 closed-loop days, 2530 sensor-augmented pump days).
We excluded 830 days when closed loop was operational
for <80% of the time and also excluded 292 days with no
meal data.
The distribution of behavioral patterns including eating
habits, insulin boluses, and fingerstick measurements is shown
in Figure 1. The number of snacks per day and the number of
correction boluses per day displayed the highest relative var-
iability among participants. Table 1 compares behavioral
patterns between closed-loop and control periods. Eating
habits were not affected by the use of closed loop with an
identical number of reported meals and snacks, and no
change in meal or the snack size. The number of fingerstick
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glucose measurements was also similar—the analysis com-
bines calibrating and noncalibrating fingerstick glucose
measurements. The total number of insulin boluses was re-
duced during closed-loop than during sensor-augmented
pump therapy by mean 1.0 bolus per day [95% confidence
interval (95% CI) 0.6–1.4; P < 0.001] mainly because of less
frequent administration of correction boluses reduced by
mean 0.7 bolus per day (95% CI 0.4–1.0; P < 0.001) so that
around 0.6 correction boluses were administered per day
during closed loop. Of these correction boluses, around 0.5
(0.484) were given during daytime (07:00–23:00) and around
0.1 (0.135) were given during night-time (23:00–07:00).
Associations between behavioral patterns and glucose con-
trol are reported in Table 2. The increased size but not the
number of snacks that an individual consumed was associated
with deteriorated glucose control, including increased mean
sensor glucose, glucose variability, and postinterventionHbA1c.
This applied to both closed-loop and sensor-augmented pump
FIG. 1. Distribution of behavioral patterns during closed-loop (n = 32) and control (n = 33) periods. Values are relative to
population means (100%).
Table 1. Behavioral Patterns and Glucose Control During Closed-Loop and Control Periods
Closed-loop
(n= 32)
Control
(n= 33)
Paired difference
(95% CI)a P
No. of main meals per day 2.9 – 0.6 2.7 – 0.8 -0.2 (-0.4 to 0.07) 0.166
Size of main meal per day (grams of CHO) 51.2 – 12.3 52.7 – 13.9 1.0 (-0.7 to 3.0) 0.243
No. of snacks per day 1.2 – 0.9 1.1 – 0.8 -0.1 (-0.3 to 0.1) 0.386
Size of snacks per day (grams of CHO) 19.2 – 3.8 19.4 – 4.4 0.004 (-0.8 to 0.8) 0.992
No. of boluses per day 4.4 – 0.9 5.4 – 1.5 1.0 (0.6 to 1.4) <0.001
No. of small boluses per dayb 2.4 – 1.0 3.0 – 1.5 0.7 (0.2 to 1.0) 0.003
No. of correction boluses per dayc 0.6 – 0.5 1.3 – 0.9 0.7 (0.4 to 1.0) <0.001
No. of fingerstick measurements per day 4.2 – 1.3 4.3 – 1.5 0.01 (-0.3 to 0.4) 0.950
Mean sensor glucose (mmol/L)d 8.7 – 1.1 9.3 – 1.6 0.6 (0.3 to 1.0) <0.001
Glucose variability (SD, mmol/L)d 3.4 – 0.7 3.6 – 0.7 0.3 (0.1 to 0.4) <0.001
Postintervention HbA1c (%)d 7.3 – 0.8 7.6 – 1.1 0.3 (0.1 to 0.5) 0.003
Mean –SD values are reported.
aMean differences (closed-loop period minus control period), with 95% CIs for the mean.
bSmall boluses include those boluses that did not exceed 10% of the subject’s average total daily dose.
cCorrection boluses include small boluses 15min or more apart from a meal and delivered when the sensor glucose reading exceeded
8mmol/L.
dAs reported previously.8
95% CI, 95% confidence interval; CHO, carbohydrates; SD, standard deviation.
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periods (P<0.05) with a particular effect on glucose variability
during sensor-augmented pump intervention (P< 0.01).Glucose
variability was positively associated with the size of main meals
during closed-loop period (P< 0.05). The number of fingerstick
glucose measurements was associated with reduced glucose
variability during sensor-augmented pump period (P<0.05) but
not during closed-loop period. No further significant associa-
tions were found. About one half (47%) of between-subject
variance of glucose variability was explained by behavioral
patterns during sensor-augmented pump period. For other glu-
cose control end points, the linear regression model explained
about one-third (30%–33%) of between-subject variance during
closed-loop and sensor-augmented pump periods.
Discussion
The results demonstrate that the number of correction
boluses decreases during closed-loop period, reducing the
total number of insulin boluses administered per day com-
pared with sensor-augmented pump therapy reducing therapy
burden. The size but not the number of snacks that an indi-
vidual consumes is associated with poorer glycemic control
as measured by mean glucose, glucose variability, and
HbA1c during sensor-augmented pump and closed-loop in-
terventions. The effect of snack size on glucose variability
appears to be diminished during closed-loop intervention.
Other studies investigated associations between behavioral
patterns and glycemic control. Pfu¨tzner et al.9 reported that
pump users performing more frequent fingerstick glucose
measurements have better glycemic control and lower glu-
cose variability. This is consistent with our findings that
during sensor-augmented pump therapy, the number of fin-
gerstick measurements is associated with lower glucose
variability, whereas displaying no such trend during closed-
loop period. We determined that the combined effect of be-
havioral patterns during sensor-augmented pump therapy
explains greater amount of glucose variability than when
closed-loop period was applied (47% vs. 30%, respectively).
Our results suggest that the use of a closed-loop system
lessens the influence of behavioral patterns on glucose vari-
ability but not on mean glucose levels.
Data from T1D exchange3 registry showed that the fre-
quency of self-monitoring of blood glucose is strongly cor-
related with lower HbA1c levels in all age groups even after
adjusting for confounding factors such as insurance coverage,
household income, and insulin pump therapy. In this study,
HbA1c levels were not associated with frequency of self-
monitoring of blood glucose that can be explained by the use
of continuous glucose monitoring, which enables glucose
values and the rate of glucose change to be freely inspected
without resorting to fingerstick glucose measurements.
Delahanty and Halford10 examined self-reported diet-
related behaviors during the Diabetes and Control and Com-
plications Trial and reported that overtreating hypoglycemia
and consuming extra snacks outside meal plan were associated
with higher HbA1c levels. Øverby et al.11 examined the as-
sociation between skipping meals and snacking events in
children and adolescents and observed that those who skip
meals and havemore snacks have poorer glycemic control.Our
results show that the carbohydrate content but not the number
of snacks per day is the diet-attributable behavior that signifi-
cantly affects glucose control and particularly glucose vari-
ability. This finding may be explained by the anticipated
simple-carbohydrates-rich content of snacks as opposed to
larger meals that are expected to contain complex carbohy-
drates and other nutrients, slowing down carbohydrate ab-
sorption. Further research is warranted to confirm our findings.
The strength of our study is the relatively long duration of
the interventions and the randomized multicenter controlled
design supporting generalizability. Insulin bolusing and fin-
gerstick measurements were reliably downloaded from the
glucometer and insulin pump. The study is limited by the
self-reported nature of meal-related information, which may
not be fully reliable. This is, in part, because of the common
challenge that patients face with carbohydrate counting, and
specifically the potential impact of limited carbohydrate ac-
curacy during the use of closed-loop or sensor-augmented
pump therapy. Some of the common challenges include un-
reported meals, under or over estimation of carbohydrates,
and multiple reporting of the same carbohydrate intake. We
did not correct P values for multiple comparisons, given the
hypotheses generating nature of the investigations.
Table 2. Correlations Between Behavioral Patterns and Glucose During
Closed-Loop and Control Periods
Closed-loop (n = 32) Control (n = 33)
Mean
glucose
Glucose
variability
Postintervention
HbA1c
Mean
glucose
Glucose
variability
Postintervention
HbA1c
No. of main meals per day 0.030 0.003 0.045 -0.06 -0.202 0.015
Size of main meal per day (grams of CHO) 0.306 0.377* 0.276 0.268 0.317 0.209
No. of snacks per day 0.077 -0.136 0.058 -0.147 -0.214 -0.088
Size of snacks per day (grams of CHO) 0.404* 0.365* 0.441* 0.388* 0.531** 0.428*
No. of boluses per day -0.064 -0.221 0.031 -0.018 -0.172 -0.087
No. of small boluses per day -0.050 -0.245 0.017 -0.181 -0.325 -0.229
No. of correction boluses per day 0.092 0.004 0.134 -0.015 -0.097 -0.106
No. of fingerstick measurements per day -0.205 -0.270 -0.259 -0.278 -0.367* -0.193
R2 of the linear regression model (%)a 31 30 31 32 47* 33
Pearson correlation coefficient is reported.
*P< 0.05.
**P< 0.01.
aThe linear regression model included all of the behavioral traits already described.
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In conclusion, we document that although eating patterns
and self-blood glucose monitoring do not depend on the
method of therapy, individuals using the closed-loop period
show a decrease in the number of correction boluses. The size
of snacks appears to worsen glucose control, possibly be-
cause of carbohydrate-rich content of snacks.
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